GlassScriptPhysician profile
Sarah C Jarrell
NPI 1104153030
$4,355.00
in general payments reported to CMS, 2019-2025
32 companies · $498 in 2025
The $498 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $707 · 2020: $269 · 2021: $865 · 2022: $608 · 2023: $669 · 2024: $738 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $580.40 | 2021-2025 | |
| Abbvie INC. | $464.42 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $412.35 | 2019-2024 | |
| Astellas Pharma US INC | $388.44 | 2019-2025 | Veozah, Myrbetriq, Cresemba |
| Exeltis, USA INC. | $241.86 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $205.43 | 2019-2022 | |
| Hologic Sales and Service, LLC | $194.65 | 2019-2025 | Acessa Provu System, Novasure, Aptima |
| Sumitomo Pharma America, INC. | $183.78 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $149.40 | 2021-2022 | |
| Millicent US INC | $147.01 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Organon LLC | $136.51 | 2022-2025 | Nexplanon |
| Evofem Biosciences, INC. | $130.51 | 2020-2023 | Phexxi |
| Caldera Medical, INC | $130.11 | 2024 | Desara |
| Amag Pharmaceuticals, INC. | $126.22 | 2019 | |
| Channel Medsystems, INC. | $101.90 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $100.68 | 2021-2022 | |
| Pfizer INC. | $78.97 | 2022-2025 | |
| Agile Therapeutics, INC. | $77.71 | 2021-2023 | Twirla |
| Daiichi Sankyo INC. | $74.97 | 2019-2020 | |
| Duchesnay USA Incorporated | $48.61 | 2019 | |
| Allergan, INC. | $46.91 | 2019 | |
| Aspira Women'S Health INC | $45.75 | 2022-2023 | Ova1 |
| Amgen INC. | $44.24 | 2019-2021 | |
| Scynexis, INC. | $41.85 | 2022 | |
| Lupin INC. | $40.97 | 2019-2021 | |
| Avion Pharmaceuticals | $39.08 | 2019-2021 | |
| Radius Health, INC. | $36.24 | 2019 | |
| Roche Diagnostics Corporation | $24.34 | 2019 | |
| Sage Therapeutics, LLC | $23.24 | 2024 | |
| Axonics, INC. | $13.38 | 2023 | Axonics |
| Merck Sharp & Dohme LLC | $12.90 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Jarrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.